BioTuesdays

Category - Markets

Point Biopharma Logo
Markets

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

December 1, 2021
Citius Logo
Markets

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

November 30, 2021
Freeline Therapeutics
Markets

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

November 29, 2021
Acurx Pharmaceuticals
Markets

Maxim starts Acurx Pharma at buy; PT $12

Maxim Group initiated coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $12 price target. The stock closed at $4.89 on Nov. 26. Acurx is developing ibezapolstat, a member of an emerging new class...

November 29, 2021
Mdx Health
Markets

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

November 29, 2021
opsens logo
Markets

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...

November 23, 2021
Aura Biosciences
Markets

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

November 23, 2021
Airsculpt Technologies
Markets

SVB Leerink starts Airsculpt at OP; PT $26

SVB Leerink launched coverage of Airsculpt Technologies (NASDAQ:AIRS) with an “outperform” rating and price target of $26. The stock closed at $13.61 on Nov. 22. Airsculpt has created an innovative luxury consumer brand...

November 23, 2021